基本信息
浏览量:16
职业迁徙
个人简介
Sir Zumla’s research focuses on killer infectious diseases affecting adults and children globally. His R&D networks span across all continents.
1). RESPIRATORY TRACT INFECTIONS (RTIs):Tuberculosis (TB), TB-HIV/AIDS co-infections, MERS,COVID-19, Community & Hospital acquired pneumonia. Transmission of RTIs including AMR at mass gathering religious and sporting events. A novel 'Mass Gatherings Medicine' initiative with several basic science, translational clinical and operational studies on infections with epidemic potential.
2). EMERGING AND RE-EMERGING INFECTIOUS DISEASES with epidemic potential which threaten global health security: i).Multi-drug resistant TB. ii).Zoonotic infections (MERS-CoV, SARS-CoV, COVID-19, EBOLA, Chikungunya, Monkeypox, Lassa Fever, Dengue, iii).Antibiotic resistant pathogens.
a). ONE-HUMAN-ENVIRONMENTAL-ANIMAL HEALTH (ONE-HEALTH): EPIDEMIOLOGICAL, PATHOGENESIS, TRANSLATIONAL CLINICAL & AUTOPSY STUDIES: Sentinel cross-continental epidemiological and clinical studies defined the importance of TB, and showed the emergence of extensively drug resistant TB in Eastern Europe and Southern Africa. Pioneering community and hospital based autopsy studies of children and adults defining pathogenesis of killer RTIs including TB, SARS-CoV-2/COVID-19.
b) CLINICAL TRIALS EVALUATING DIAGNOSTICS, DRUGS AND HOST-DIRECTED THERAPIES: Sir Zumla leads several international, multi-country collaborative networks between academics, health care workers, healthcare providers, and policy makers for the conduct of multi-centre GLP/GCP clinical trials.
c). RESEARCH INTO THE EPIDEMIOLOGY, DIAGNOSIS, TREATMENT AND PREVENTION OF KILLER RESPIRATORY INFECTIONS INCLUDING MDR-TB, MERS-COV AND SARS-CoV-2 (COVID-19):Laboratory and translational clinical research on longitudinal cohorts ofpatients is leading to development and evaluation of rapid POC diagnostics and biomarkers for response to treatment, cure and relapse. Novel biomarkers of cytokine ratios, urine and filter paper based TB diagnostics tests have been developed. Evaluation of new and novel rapid TB diagnostic technologies in inpatient paediatric and adult wards.
d). AUTOPSY AND PATHOGENESIS STUDIES:
Sir Zumla and teams are renowned for their leadership of autopsy studies of children and adults.
1). RESPIRATORY TRACT INFECTIONS (RTIs):Tuberculosis (TB), TB-HIV/AIDS co-infections, MERS,COVID-19, Community & Hospital acquired pneumonia. Transmission of RTIs including AMR at mass gathering religious and sporting events. A novel 'Mass Gatherings Medicine' initiative with several basic science, translational clinical and operational studies on infections with epidemic potential.
2). EMERGING AND RE-EMERGING INFECTIOUS DISEASES with epidemic potential which threaten global health security: i).Multi-drug resistant TB. ii).Zoonotic infections (MERS-CoV, SARS-CoV, COVID-19, EBOLA, Chikungunya, Monkeypox, Lassa Fever, Dengue, iii).Antibiotic resistant pathogens.
a). ONE-HUMAN-ENVIRONMENTAL-ANIMAL HEALTH (ONE-HEALTH): EPIDEMIOLOGICAL, PATHOGENESIS, TRANSLATIONAL CLINICAL & AUTOPSY STUDIES: Sentinel cross-continental epidemiological and clinical studies defined the importance of TB, and showed the emergence of extensively drug resistant TB in Eastern Europe and Southern Africa. Pioneering community and hospital based autopsy studies of children and adults defining pathogenesis of killer RTIs including TB, SARS-CoV-2/COVID-19.
b) CLINICAL TRIALS EVALUATING DIAGNOSTICS, DRUGS AND HOST-DIRECTED THERAPIES: Sir Zumla leads several international, multi-country collaborative networks between academics, health care workers, healthcare providers, and policy makers for the conduct of multi-centre GLP/GCP clinical trials.
c). RESEARCH INTO THE EPIDEMIOLOGY, DIAGNOSIS, TREATMENT AND PREVENTION OF KILLER RESPIRATORY INFECTIONS INCLUDING MDR-TB, MERS-COV AND SARS-CoV-2 (COVID-19):Laboratory and translational clinical research on longitudinal cohorts ofpatients is leading to development and evaluation of rapid POC diagnostics and biomarkers for response to treatment, cure and relapse. Novel biomarkers of cytokine ratios, urine and filter paper based TB diagnostics tests have been developed. Evaluation of new and novel rapid TB diagnostic technologies in inpatient paediatric and adult wards.
d). AUTOPSY AND PATHOGENESIS STUDIES:
Sir Zumla and teams are renowned for their leadership of autopsy studies of children and adults.
研究兴趣
论文共 986 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
medRxiv (Cold Spring Harbor Laboratory) (2024)
The Lancet Planetary Health (2024)
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2024)
Jean B Nachega, Jean‑Jacques Muyembe‑Tamfum, Francine Ntoumi, Placide Mbala‑Kingebeni,Alimuddin Zumla
Lancet (London, England)no. 10458 (2024): 1099-1100
Respirology (Carlton, Vic) (2024)
Moses J Bockarie,Rashid Ansumana, Shingai Grace Machingaidze,Dziedzom K. de Souza,Patrick Fatoma,Alimuddin Zumla,Shui-Shan Lee
International Journal of Infectious Diseases (2024): 107011-107011
Majid Alshamrani, Fayssal Farahat, Mohammed Alzunitan, Musallam Abu Hasan, Nisreen Alsherbini,Ali Albarrak,Sameera M Al Johani, Atef shibl, Jaffar A. Al-Tawfiq,Alimuddin Zumla, Ziad Memish
Journal of Infection and Public Healthpp.102547, (2024)
加载更多
作者统计
#Papers: 984
#Citation: 52819
H-Index: 109
G-Index: 203
Sociability: 9
Diversity: 0
Activity: 8
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn